Fairvalue-Calculator Fairvalue-Calculator
EN DE

Anika Therapeutics, Inc (ANIK) Fair Value & Analysis

Healthcare · US · Market cap $189M

Price$14.73
Fair Value$6.61
Upside-55.1%
Quality95/100
Evidence: Medium Range $5.33 – $7.89

Fair value as of: Jun 25, 2026

Analysis

Anika Therapeutics, Inc (ANIK) currently trades at $14.73, while our model-based Fair Value estimate is $6.61 — implying the stock looks roughly 55.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Anika Therapeutics, Inc (ANIK) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $6.61 versus a price of $14.73 — about −55% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ANIK?
Our 21-model fair value for Anika Therapeutics, Inc is $6.61 (as of Jun 25, 2026), built from audited fundamentals. The current price is $14.73.
What is the quality score of ANIK?
Anika Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.